Cardiac amyloidosis: An update on diagnosis and treatment.

Authors:
Joseph P Donnelly
Joseph P Donnelly
Colorado State University
United States
Mazen Hanna
Mazen Hanna
Cleveland Clinic
Cleveland | United States

Cleve Clin J Med 2017 Dec;84(12 Suppl 3):12-26

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.

Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due to enhanced clinical awareness and better diagnostic imaging. CA is becoming of heightened interest to the cardiology community given more effective treatment strategies for light chain amyloidosis (AL), as well as emerging therapies for transthyretin amyloidosis (ATTR). Furthermore, reversing amyloid deposition in affected organs using monoclonal antibodies is actively being tested in clinical trials. A high index of suspicion and a systematic approach to the diagnosis of CA can lead to referral to a center of expertise for timely treatment.

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.84.s3.02DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
December 2017
11 Reads

Publication Analysis

Top Keywords

cardiac amyloidosis
8
amyloidosis attr
4
transthyretin amyloidosis
4
therapies transthyretin
4
attr reversing
4
reversing amyloid
4
deposition organs
4
amyloid deposition
4
emerging therapies
4
amyloidosis well
4
effective treatment
4
community effective
4
cardiology community
4
treatment strategies
4
strategies light
4
organs monoclonal
4
light chain
4
well emerging
4
monoclonal antibodies
4
lead referral
4

Similar Publications